Cancer Biotech NantKwest's $207M IPO Trumps Expectations
California-based NantKwest Inc. rumbled onto the market Tuesday after its $207 million initial public offering trumped expectations and rocketed the cancer treatment developer into the ranks of the largest-ever biotech debuts,...To view the full article, register now.
Already a subscriber? Click here to view full article